Sector consensus Vanda Pharmaceuticals Inc.
Equities
VNDA
US9216591084
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.280 USD | -1.72% |
|
0.00% | -28.80% |
| May. 07 | Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026 | |
| May. 06 | Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 14.9 | +133.18% | 5 | ||||||
| 846.68 | +21.96% | 15 | ||||||
| 145.41 | +41.16% | 17 | ||||||
| 203.3 | +75.83% | 20 | ||||||
| 107.94 | +36.97% | 17 | ||||||
| 40.13 | +40.99% | 21 | ||||||
| 2,313.13 | +37.36% | 15 | ||||||
| 150.59 | +39.52% | 21 | ||||||
| 22.29 | +66.12% | 14 | ||||||
| 533.85 | +22.78% | 17 | ||||||
| 49.06 | -3.99% | 17 | ||||||
| 674.36 | +24.91% | 14 | ||||||
| 87.58 | +9.9% | 12 | ||||||
| 105 | +33.52% | 19 | ||||||
| 766.5 | -1.98% | 6 | ||||||
| 96.82 | +23.44% | 15 | ||||||
| 15.25 | +87.12% | 4 | ||||||
| - | - | 770,000 | +46.11% | 1 | ||||
| 142.06 | +36.06% | 18 | ||||||
| Average | 40,858.68 | +40.58% | 14 | ||||||
| Weighted average by Cap. | 22,265.73 | +36.33% | 16 |
- Stock Market
- Equities
- VNDA Stock
- Sector Vanda Pharmaceuticals Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
